Predicate |
Object |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-26 |
classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-165 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-44 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-365 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-26 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-00 |
filingDate |
2002-07-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_10b2daf9a89784a7ae6c2d97d8f74a5e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b085b56997582439cb30192bf07b24c4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b4c14f45911623beee4207711e4885a |
publicationDate |
2003-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
US-2003109418-A1 |
titleOfInvention |
Methods for identifying compounds for inhibition of neoplastic lesions, and pharmaceutical compositions containing such compounds |
abstract |
This invention provides pharmaceutical compositions containing compounds for the treatment of neoplasia in mammals. The increase in PKG activity of a compound is determined along with COX inhibitory activity. Growth inhibitory and apoptosis inducing effects on cultured tumor cells are also determined. Compounds that exhibit increase PKG activity, growth inhibition and apoptosis induction, but preferably not substantial prostaglandin inhibitory activity, are desirable for the treatment of neoplasia. |
priorityDate |
1999-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |